EE03855B1 - Alfusosiinhüdrokloriidi reguleeritult vabastav tablett - Google Patents

Alfusosiinhüdrokloriidi reguleeritult vabastav tablett

Info

Publication number
EE03855B1
EE03855B1 EEP199900090A EE9900090A EE03855B1 EE 03855 B1 EE03855 B1 EE 03855B1 EE P199900090 A EEP199900090 A EE P199900090A EE 9900090 A EE9900090 A EE 9900090A EE 03855 B1 EE03855 B1 EE 03855B1
Authority
EE
Estonia
Prior art keywords
controlled release
release tablet
alfuzosin hydrochloride
hydrochloride controlled
alfuzosin
Prior art date
Application number
EEP199900090A
Other languages
English (en)
Estonian (et)
Other versions
EE9900090A (et
Inventor
Xavier Jarreau Fran�ois
Maggi Lauretta
Conte Ubaldo
Grenier Pascal
Vergnault Guy
Dufour Alain
Rauch-Desanti Cl�mence
Original Assignee
Synthlabo
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26232935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03855(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9610551A external-priority patent/FR2752737B1/fr
Application filed by Synthlabo, Jagotec Ag filed Critical Synthlabo
Publication of EE9900090A publication Critical patent/EE9900090A/xx
Publication of EE03855B1 publication Critical patent/EE03855B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP199900090A 1996-08-29 1997-08-22 Alfusosiinhüdrokloriidi reguleeritult vabastav tablett EE03855B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9610551A FR2752737B1 (fr) 1996-08-29 1996-08-29 Comprime a liberation controlee de chlorhydrate d'alfuzosine
FR9704386 1997-04-10
PCT/FR1997/001515 WO1998008515A1 (fr) 1996-08-29 1997-08-22 Comprime a liberation controlee de chlorhydrate d'alfuzosine

Publications (2)

Publication Number Publication Date
EE9900090A EE9900090A (et) 1999-10-15
EE03855B1 true EE03855B1 (et) 2002-10-15

Family

ID=26232935

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900090A EE03855B1 (et) 1996-08-29 1997-08-22 Alfusosiinhüdrokloriidi reguleeritult vabastav tablett

Country Status (37)

Country Link
US (1) US6149940A (bg)
EP (1) EP0938318B1 (bg)
JP (1) JP3797388B2 (bg)
KR (1) KR100364328B1 (bg)
CN (2) CN100335057C (bg)
AP (1) AP1107A (bg)
AR (1) AR009312A1 (bg)
AT (1) ATE200864T1 (bg)
AU (1) AU724490B2 (bg)
BG (1) BG63768B1 (bg)
BR (1) BR9713237B1 (bg)
CA (1) CA2264250C (bg)
CO (1) CO4920217A1 (bg)
CY (1) CY2284B1 (bg)
CZ (1) CZ295066B6 (bg)
DE (1) DE69704712T2 (bg)
DK (1) DK0938318T3 (bg)
EE (1) EE03855B1 (bg)
ES (1) ES2159400T3 (bg)
GR (1) GR3036291T3 (bg)
HK (1) HK1020875A1 (bg)
HU (1) HU228007B1 (bg)
IL (1) IL128146A (bg)
IS (1) IS2091B (bg)
MX (1) MXPA99001958A (bg)
NO (1) NO326206B1 (bg)
NZ (1) NZ334018A (bg)
OA (1) OA10983A (bg)
PL (1) PL191546B1 (bg)
PT (1) PT938318E (bg)
RU (1) RU2183459C2 (bg)
SI (1) SI0938318T1 (bg)
SK (1) SK284388B6 (bg)
TR (1) TR199900289T2 (bg)
TW (1) TW522023B (bg)
UA (1) UA69374C2 (bg)
WO (1) WO1998008515A1 (bg)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720471B1 (en) 1998-04-28 2004-04-13 The Procter & Gamble Company Absorbent articles having reduced rewet with distribution materials positioned underneath storage material
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
JP2003521507A (ja) 2000-02-04 2003-07-15 ディポメド，インコーポレイティド ゼロ次薬物放出に接近するシェル−コア剤形
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
FR2820318B1 (fr) * 2001-02-08 2005-12-23 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant un principe actif et comprime obtenu
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US7309444B2 (en) * 2002-08-29 2007-12-18 Stellar Technology Company Layered tablet water treatment compositions and method of use
US6852238B2 (en) * 2002-08-29 2005-02-08 Steller Technology Company Layered tablet water treatment compositions and method of use
EP1551372B8 (en) 2002-09-20 2018-08-01 Alpharma Pharmaceuticals LLC Sequestering subunit and related compositions and methods
MXPA05004338A (es) * 2002-10-22 2005-06-22 Ranbaxy Lab Ltd Composiciones de liberacion sostenida que contienen alfuzosin.
CN1993112A (zh) * 2004-07-29 2007-07-04 赛诺菲-安万特 用于具有高度pH依赖性溶解度的活性成分的控释的药物多层片剂
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
US20060062845A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
US20060062846A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
ITMI20050391A1 (it) * 2005-03-11 2006-09-12 Ph & T S P A Formulazioni a rilascio controllato di alfuzosin
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
DK1889198T3 (da) 2005-04-28 2015-02-09 Proteus Digital Health Inc Farma-informatiksystem
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
BRPI0611535B1 (pt) 2005-05-05 2021-11-30 Sensient Flavors Inc Método para processar células de levedura para produzir beta-glucanos e mananas
US20070185232A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20070185235A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
US20070185237A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20090238776A1 (en) * 2005-11-09 2009-09-24 Arif Ali Baig Oral Care Compositions and Methods
US20070185236A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
US7834066B2 (en) * 2005-11-09 2010-11-16 The Procter & Gamble Company Denture adhesive articles
US20070185233A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20070129460A1 (en) * 2005-11-09 2007-06-07 Jayanth Rajaiah Denture adhesive articles
US8206742B2 (en) * 2006-01-12 2012-06-26 Wockhardt Ltd. Sustained release compositions of alfuzosin
CA2650920C (en) 2006-05-02 2016-10-18 Proteus Biomedical, Inc. Patient customized therapeutic regimens
EP2526932B1 (en) 2006-06-19 2017-06-07 Alpharma Pharmaceuticals LLC Pharmaceutical composition
US20080003286A1 (en) * 2006-06-29 2008-01-03 Sathya Narayana Vemula Sustained delivery alfuzosin compositions
US20080181947A1 (en) * 2006-09-26 2008-07-31 Astellas Pharma Inc. Controlled release dosage form of tacrolimus
US20080095844A1 (en) * 2006-10-23 2008-04-24 Rajhans Sujay Kamalakar Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
SG175681A1 (en) 2006-10-25 2011-11-28 Proteus Biomedical Inc Controlled activation ingestible identifier
EP2069004A4 (en) 2006-11-20 2014-07-09 Proteus Digital Health Inc PERSONAL HEALTH SIGNAL RECEIVERS WITH ACTIVE SIGNAL PROCESSING
US20080138412A1 (en) * 2006-12-06 2008-06-12 Fu-Yung Lin Sustained release alfuzosin hydrochl formulation and method for their production
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
WO2008073388A2 (en) * 2006-12-11 2008-06-19 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making and methods of use
EP2119442A4 (en) 2006-12-28 2010-12-15 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION WITH TACROLIMUS MAINTAINED RELEASE
MY165532A (en) 2007-02-01 2018-04-02 Proteus Digital Health Inc Ingestible event marker systems
AU2008216170B2 (en) 2007-02-14 2012-07-26 Otsuka Pharmaceutical Co., Ltd. In-body power source having high surface area electrode
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
US9270025B2 (en) 2007-03-09 2016-02-23 Proteus Digital Health, Inc. In-body device having deployable antenna
WO2008112577A1 (en) 2007-03-09 2008-09-18 Proteus Biomedical, Inc. In-body device having a multi-directional transmitter
US8115618B2 (en) 2007-05-24 2012-02-14 Proteus Biomedical, Inc. RFID antenna for in-body device
PT2192946T (pt) 2007-09-25 2022-11-17 Otsuka Pharma Co Ltd Dispositivo no corpo com amplificação de sinal dipolo virtual
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
ES2840773T3 (es) 2008-03-05 2021-07-07 Otsuka Pharma Co Ltd Sistemas y marcadores de eventos ingeribles de comunicación multimodo
JP5373069B2 (ja) * 2008-06-04 2013-12-18 ザ プロクター アンド ギャンブル カンパニー 義歯接着剤組成物及び方法
CN102159134B (zh) 2008-07-08 2015-05-27 普罗透斯数字保健公司 可摄取事件标记数据框架
WO2010019778A2 (en) 2008-08-13 2010-02-18 Proteus Biomedical, Inc. Ingestible circuitry
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
CA2750158A1 (en) 2009-01-06 2010-07-15 Proteus Biomedical, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
TWI544917B (zh) 2009-01-06 2016-08-11 波提亞斯數位康健公司 醫藥劑量傳送系統
US20100183717A1 (en) * 2009-01-16 2010-07-22 Kristin Arnold Controlled-release formulations
GB2480965B (en) 2009-03-25 2014-10-08 Proteus Digital Health Inc Probablistic pharmacokinetic and pharmacodynamic modeling
MX2011011506A (es) 2009-04-28 2012-05-08 Proteus Biomedical Inc Marcadores de eventos ingeribles altamente confiables y metodos para utilizar los mismos.
WO2010132331A2 (en) 2009-05-12 2010-11-18 Proteus Biomedical, Inc. Ingestible event markers comprising an ingestible component
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
CA2790116C (en) 2010-03-10 2016-02-16 The Procter & Gamble Company Denture adhesive compositions
PT2554168T (pt) 2010-03-29 2018-02-28 Astellas Pharma Inc Composição farmacêutica de libertação controlada
US9597487B2 (en) 2010-04-07 2017-03-21 Proteus Digital Health, Inc. Miniature ingestible device
WO2011124953A2 (en) * 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
TWI557672B (zh) 2010-05-19 2016-11-11 波提亞斯數位康健公司 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
JP2014504902A (ja) 2010-11-22 2014-02-27 プロテウス デジタル ヘルス， インコーポレイテッド 医薬品を有する摂取可能なデバイス
CN102475690B (zh) * 2010-11-30 2016-06-01 安国药品株式会社 内含盐酸阿夫唑嗪的缓释片剂
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
CN103827914A (zh) 2011-07-21 2014-05-28 普罗秋斯数字健康公司 移动通信设备、系统和方法
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
CN104487347B (zh) 2012-07-23 2017-09-01 普罗秋斯数字健康公司 用于制造包括电子器件的片剂的方法和系统
AU2013331417B2 (en) 2012-10-18 2016-06-02 Proteus Digital Health, Inc. Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
TWI659994B (zh) * 2013-01-29 2019-05-21 美商普羅托斯數位健康公司 高度可膨脹之聚合型薄膜及包含彼之組成物
WO2014144738A1 (en) 2013-03-15 2014-09-18 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
EP3968263A1 (en) 2013-06-04 2022-03-16 Otsuka Pharmaceutical Co., Ltd. System, apparatus and methods for data collection and assessing outcomes
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
WO2017078557A1 (ru) * 2015-11-05 2017-05-11 Анатолий Викторович ЗАЗУЛЯ Изготовление таблетки с механизмом повышения терапевтической эффективности лекарственного средства нанодозой аналога
CN111493872B (zh) 2016-07-22 2023-05-05 大冢制药株式会社 可摄入事件标记的电磁感测和检测
US10820831B2 (en) 2016-10-26 2020-11-03 Proteus Digital Health, Inc. Methods for manufacturing capsules with ingestible event markers
CN114209668B (zh) * 2022-01-13 2023-01-31 山东新时代药业有限公司 一种盐酸阿夫唑嗪缓释制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2582513B1 (fr) * 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
GB9311191D0 (en) * 1993-05-29 1993-07-14 Danbiosyst Uk Controlled release drug formulation
FR2717388B1 (fr) * 1994-03-21 1996-11-22 Synthelabo Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.

Also Published As

Publication number Publication date
CN100335057C (zh) 2007-09-05
AP1107A (en) 2002-09-20
NO990944D0 (no) 1999-02-26
PL331862A1 (en) 1999-08-16
EE9900090A (et) 1999-10-15
BR9713237B1 (pt) 2009-01-13
AU4020197A (en) 1998-03-19
ES2159400T3 (es) 2001-10-01
SK284388B6 (sk) 2005-02-04
PL191546B1 (pl) 2006-06-30
MXPA99001958A (es) 2005-09-08
NO326206B1 (no) 2008-10-20
IS2091B (is) 2006-03-15
WO1998008515A1 (fr) 1998-03-05
SI0938318T1 (en) 2001-12-31
AR009312A1 (es) 2000-04-12
KR20000035929A (ko) 2000-06-26
CA2264250A1 (en) 1998-03-05
AU724490B2 (en) 2000-09-21
GR3036291T3 (en) 2001-10-31
IS4964A (is) 1999-01-29
CY2284B1 (en) 2003-07-04
JP3797388B2 (ja) 2006-07-19
CZ295066B6 (cs) 2005-05-18
DE69704712T2 (de) 2001-11-29
ATE200864T1 (de) 2001-05-15
IL128146A0 (en) 1999-11-30
CO4920217A1 (es) 2000-05-29
CN1155382C (zh) 2004-06-30
DE69704712D1 (de) 2001-06-07
CZ65599A3 (cs) 1999-06-16
CN1543954A (zh) 2004-11-10
EP0938318A1 (fr) 1999-09-01
HUP9903428A3 (en) 2000-04-28
OA10983A (fr) 2003-03-04
NZ334018A (en) 1999-06-29
TW522023B (en) 2003-03-01
RU2183459C2 (ru) 2002-06-20
JP2000514462A (ja) 2000-10-31
HU228007B1 (en) 2012-08-28
TR199900289T2 (xx) 2000-12-21
DK0938318T3 (da) 2001-08-20
BG103138A (bg) 1999-09-30
KR100364328B1 (ko) 2002-12-26
CA2264250C (en) 2005-07-05
BG63768B1 (bg) 2002-12-29
BR9713237A (pt) 2000-04-04
AP9901470A0 (en) 1999-03-31
CN1228700A (zh) 1999-09-15
IL128146A (en) 2001-01-11
SK27099A3 (en) 1999-12-10
US6149940A (en) 2000-11-21
EP0938318B1 (fr) 2001-05-02
HK1020875A1 (en) 2000-05-26
NO990944L (no) 1999-04-27
HUP9903428A2 (hu) 2000-02-28
PT938318E (pt) 2001-10-30
UA69374C2 (uk) 2004-09-15

Similar Documents

Publication Publication Date Title
EE03855B1 (et) Alfusosiinhüdrokloriidi reguleeritult vabastav tablett
IT1303444B1 (it) Dispositivo di rilascio di farmaci.
NO20002121D0 (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
EE200100134A (et) Kiiresti vabastav tablett
DE69826338D1 (de) Sicherheitsrückhalt
PT915701E (pt) Pastilha de bromidrato de gelantamina de dissolucao rapida
DE59707194D1 (de) Direkttablettierhilfsmittel
NO980240D0 (no) Paroxetin-kontrollert frigjörings-blandinger
DE69625189D1 (de) Tablette mit gesteuerter freisetzung
DE59802126D1 (de) Tablettentestgerät
DE69737220D1 (de) Synchronisationsgerät
ID23735A (id) Tablet trovafloksasin mesilat
DE59703450D1 (de) Tablettenprüfgerät
DK0906101T3 (da) Farmaceutiske præparater med langsom frigivelse indeholdende mizolastin
EE9800209A (et) Antiglükokortikoidne ravimaine
NO983259D0 (no) Famciclovir tabletter
DE69718704T2 (de) Tablett verwendende Steuerungsvorrichtung
ZA977766B (en) Tablet with controlled release of alfuzosin hydrochloride.
NO992244D0 (no) AIDS-legemiddel
KR970053768U (ko) 정
ID21262A (id) Progestagen kristalin
ES1034978Y (es) Ladrillo encastrable
UA1246S (uk) Таблетка фармацевтична
UA25766A (uk) Пристрій для спіhеhhя бісерhого полістиролу
UA2845S (uk) Таблетка

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231